Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Fleischhacker, WW; Hinterhuber, H; Bauer, H; Pflug, B; Berner, P; Simhandl, C; Wolf, R; Gerlach, W; Jaklitsch, H; Sastre-y-Hernández, M.
A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder.
Neuropsychobiology. 1992; 26(1-2):59-64 Doi: 10.1159/000118897
Web of Science PubMed FullText FullText_MUG

Authors Med Uni Graz:
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: A multicenter randomized 4-week interindividual double-blind study was carried out in 58 hospitalized patients with major depressive disorder (DSM III 296.23, 296.22, 296.33, 296.32, 296.53 and 296.52) to test the dose-effect relationship of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram: 3 x 0.25 mg, 3 x 0.50 mg and 3 x 1.00 mg rolipram/day. With respect to the desired effect, the 3 x 0.50 mg dosage stood out from the others in almost all relevant parameters. With respect to the response rate, the efficacy of the 3 x 0.25 mg dosage was about the same as that reported in the literature for placebo. The inferior performance of the 3 x 1.00 mg dosage compared to the 3 x 0.50 mg dosage might indicate a reverse U-shaped dose-effect relationship. There was good tolerance to all three dosages. There were no findings that might cast doubt on the safety of the dosages tested.
Find related publications in this database (using NLM MeSH Indexing): Antidepressive Agents - administration and dosage; Depressive Disorder - drug therapy; Dose-Response Relationship, Drug - drug therapy; Double-Blind Method - drug therapy; Humans - drug therapy; Phosphodiesterase Inhibitors - administration and dosage; Psychiatric Status Rating Scales - administration and dosage; Pyrrolidinones - administration and dosage; Rolipram - administration and dosage
Find related publications in this database (Keywords): Rolipram; Major Depressive Disorder; Phosphodiesterase Inhibitor; Antidepressant